CATO SMS/Pharm-Olam, LLC
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CATO SMS/Pharm-Olam, LLC - overview
Established
2022
Location
-, -, US
Primary Industry
Biotechnology
About
Based in the US, and founded in 2022, CATO SMS/Pharm-Olam, LLC operates as a biopharmaceutical firm. The company was formed through a merger of CATO SMS and Pharm-Olam International LLC. As of 2022, the company employs more than 1,200 employees and operates 35 offices across North America, Latin America, Europe, India, and the Middle East. The combined company provides a suite of biotechnology solutions such as clinical trials, drug development, medical research, biometrics services, clinical pharmacology, and consulting services to the healthcare industry.
Primary Industry
Biotechnology
Sub Industries
Consulting Services, Biopharmaceuticals, Pharmaceutical Research & Development
Verticals
HealthTech
Total Amount Raised
Subscriber access only
CATO SMS/Pharm-Olam, LLC - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Merger | Completed | CATO SMS, Pharm-Olam, LLC | - |
Displaying 1 - 1 of 1
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.